HC Wainwright Reaffirms “Buy” Rating for Atossa Therapeutics (NASDAQ:ATOS)

HC Wainwright restated their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a research report report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $7.00 target price on the stock.

Several other analysts have also recently issued reports on the company. Ascendiant Capital Markets raised their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th.

Atossa Therapeutics Stock Down 2.7 %

NASDAQ:ATOS opened at $0.84 on Thursday. The firm has a market capitalization of $105.91 million, a P/E ratio of -3.83 and a beta of 1.26. Atossa Therapeutics has a 52 week low of $0.72 and a 52 week high of $2.31. The company has a fifty day moving average of $1.03 and a 200 day moving average of $1.26.

Institutional Investors Weigh In On Atossa Therapeutics

Large investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in Atossa Therapeutics in the second quarter worth about $29,000. Intech Investment Management LLC bought a new position in shares of Atossa Therapeutics in the 3rd quarter worth approximately $29,000. SG Americas Securities LLC raised its position in shares of Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after acquiring an additional 30,037 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Atossa Therapeutics during the third quarter valued at approximately $75,000. Finally, JPMorgan Chase & Co. grew its stake in Atossa Therapeutics by 177.1% in the third quarter. JPMorgan Chase & Co. now owns 149,642 shares of the company’s stock worth $227,000 after purchasing an additional 95,643 shares during the period. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.